Accelerating Medical Treatments for Serious Mental Illness

This executive order directs federal agencies to accelerate research, regulatory review, and patient access to psychedelic drugs (including ibogaine compounds) for treating serious mental illness and reducing suicide rates. It creates FDA priority vouchers for breakthrough-designated psychedelics, establishes Right to Try access pathways, funds state-federal collaboration through ARPA-H, mandates interagency data sharing with VA, and requires timely DEA rescheduling of approved psychedelic products.

Federal Register Open PDF 91 FR 21709

Impact dates

Date TBD
Attorney General to complete rescheduling review for qualifying psychedelic products
Date TBD
HHS Secretary to allocate at least $50 million from ARPA-H existing funds

Market exposure

Policy exposure mapping — not investment advice. Illustrative public companies are incomplete and not recommendations.

Sectors

Pharma Technology & software

Mechanisms

Subsidy / incentiveLicensingProcurement

Role pressure

ProtectiveDomestic producer — Priority vouchers, accelerated FDA review, and $50 million in federal funding favor U.S.-based psychedelic drug developers and clinical trial operators with breakthrough-designated products
MixedDownstream manufacturer — Right to Try pathway and potential rescheduling expand addressable market, but Schedule I handling requirements and DEA compliance create operational complexity and uncertainty until rescheduling completes
ProtectiveProject developer — State governments with existing or developing psychedelic programs gain federal funding, technical assistance, and data-sharing infrastructure, reducing program development risk

Geographies

Illustrative public companies

Curated watchlist matches by sector/role — incomplete; not a recommendation.

GOOGLAlphabetAAPLAppleLLYEli LillyQQQInvesco QQQ TrustJNJJohnson & JohnsonMRKMerckMETAMeta PlatformsMSFTMicrosoftNVSNovartisNVDANVIDIAORCLOraclePFEPfizerSPYSPDR S&P 500 ETF

Confidence: medium · Policy alerts

Key directives

FDA Commissioner shall provide National Priority Vouchers to appropriate psychedelic drugs with Breakthrough Therapy designation
FDA and DEA shall establish Right to Try pathway for psychedelic drugs including Schedule I handling authorizations
HHS Secretary shall allocate at least $50 million from ARPA-H existing funds to support state psychedelic programs
HHS and FDA shall collaborate with VA and private sector to increase clinical trial participation and data sharing
HHS, FDA, and VA shall sign data-sharing memoranda
Attorney General shall initiate and complete rescheduling review for Phase 3-completed psychedelic products

Who is ordered

Timeline

Immediate

FDA Commissioner to issue National Priority Vouchers for qualifying psychedelic drugs
DEA/FDA to establish Right to Try access pathway with Schedule I handling authorizations
Attorney General to initiate rescheduling review for Phase 3-completed psychedelic products

Near term (90d)

HHS Secretary to allocate $50 million from ARPA-H existing funds for state-federal psychedelic programs
HHS, FDA, VA to sign data-sharing memoranda

Long term

Potential FDA approvals of breakthrough-designated psychedelic therapies
DEA rescheduling of approved psychedelic products
Expanded clinical trial participation and real-world evidence generation
Potential reduction in veteran and general population suicide rates

Risks & tensions

Schedule I substance handling creates DEA regulatory friction even with 'as quickly as practicable' rescheduling mandate
Right to Try pathway for Schedule I drugs may face legal and safety scrutiny given controlled substance restrictions
$50 million from 'existing funds' implies reprogramming without new appropriations—subject to availability caveat in Sec. 6(b)
Interagency data sharing constrained by Privacy Act and HIPAA, potentially limiting real-world evidence speed
Veteran suicide framing may politicize implementation if outcomes are slow to materialize
Psychedelic drugs remain controversial; FDA breakthrough designation does not guarantee approval or clinical validation